These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 8861551)

  • 21. Prospective randomized trial of OKT3- versus horse antithymocyte globulin-based immunosuppressive prophylaxis in heart transplantation.
    Costanzo-Nordin MR; O'Sullivan EJ; Johnson MR; Winters GL; Pifarre R; Radvany R; Zucker MJ; Scanlon PJ; Robinson JA
    J Heart Transplant; 1990; 9(3 Pt 2):306-15. PubMed ID: 2113094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative trial of immunoprophylaxis with RATG versus OKT3.
    Griffith BP; Kormos RL; Armitage JM; Dummer JS; Hardesty RL
    J Heart Transplant; 1990; 9(3 Pt 2):301-5. PubMed ID: 2113093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prophylaxis of heart transplant rejection with either antithymocyte globulin-, Minnesota antilymphocyte globulin-, or an OKT3-based protocol.
    Ladowski JS; Dillon T; Schatzlein MH; Peterson AC; Deschner WP; Beatty L; Sullivan M; Scheeringa RH; Clark WR
    J Cardiovasc Surg (Torino); 1993 Apr; 34(2):135-40. PubMed ID: 8320247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of renal allograft rejection with T10B9.1A31 or OKT3: final analysis of a phase II clinical trial.
    Waid TH; Lucas BA; Thompson JS; McKeown JW; Brown S; Kryscio R; Skeeters LJ
    Transplantation; 1997 Jul; 64(2):274-81. PubMed ID: 9256187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polyclonal versus monoclonal rejection prophylaxis after heart transplantation: a randomised study.
    Balk AH; Meeter K; Simoons ML; Brouwer RM; Zondervan PE; Mochtar B; Bos E; Weimar W
    Transpl Int; 1992; 5 Suppl 1():S476-9. PubMed ID: 14621851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
    Schroeder TJ; First MR; Mansour ME; Alexander JW; Penn I
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoclonal antibodies in renal transplantation: a review.
    Parlevliet KJ; Schellekens PT
    Transpl Int; 1992 Sep; 5(4):234-46. PubMed ID: 1418316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial.
    Kahana L; Narvarte J; Ackermann J; LeFor W; Weinstein S; Wright C; deQuesada A; Baxter J; Shires D
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): the Loyola experience.
    Costanzo-Nordin MR; O'Sullivan EJ; Hubbell EA; Zucker MJ; Pifarre R; McManus BM; Winters GL; Scanlon PJ; Robinson JA
    J Heart Transplant; 1989; 8(4):288-95. PubMed ID: 2504895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants.
    Flechner SM; Goldfarb DA; Fairchild R; Modlin CS; Fisher R; Mastroianni B; Boparai N; O'Malley KJ; Cook DJ; Novick AC
    Transplantation; 2000 Jun; 69(11):2374-81. PubMed ID: 10868643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. OKT3 prophylaxis in cadaveric kidney transplant recipients with delayed graft function.
    Cohen DJ; Benvenisty AI; Cianci J; Hardy MA
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):19-27. PubMed ID: 2510507
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prophylactic cytolytic therapy in heart transplantation: monoclonal versus polyclonal antibody therapy.
    Laske A; Gallino A; Schneider J; Bauer EP; Carrel T; Pasic M; von Segesser LK; Turina MI
    J Heart Lung Transplant; 1992; 11(3 Pt 1):557-63. PubMed ID: 1610864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.
    Webster A; Pankhurst T; Rinaldi F; Chapman JR; Craig JC
    Cochrane Database Syst Rev; 2006 Apr; (2):CD004756. PubMed ID: 16625610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Immunosuppressive therapy in renal transplantation].
    Nakamura H
    Nihon Hinyokika Gakkai Zasshi; 1993 Aug; 84(8):1359-84. PubMed ID: 8411796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rabbit antithymocyte globulin versus OKT3 induction therapy after heart-lung and lung transplantation: effect on survival, rejection, infection, and obliterative bronchiolitis.
    Barlow CW; Moon MR; Green GR; Gamberg P; Theodore J; Reitz BA; Robbins RC
    Transpl Int; 2001 Aug; 14(4):234-9. PubMed ID: 11512056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Muromonab CD3 (Orthoclone OKT3) for the prophylaxis of heart allograft rejection. Hemodynamics and respiratory tolerance].
    Guinvarc'h A; Fouillard A; Amrein C; Guillemain R; Chevalier P; Acar C; Couetil JP; Vulser C
    Ann Fr Anesth Reanim; 1995; 14(4):331-5. PubMed ID: 8572388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative efficacy of prophylactic monoclonal (OKT3) and polyclonal antibodies (ATG) in immunologic high-risk renal transplant recipients.
    Fukuuchi F; Lefrançois N; Chapuis F; Gebuhrer L; Bosshard S; Dubernard JM; Touraine JL
    Transplant Proc; 1996 Oct; 28(5):2808-9. PubMed ID: 8908070
    [No Abstract]   [Full Text] [Related]  

  • 38. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection.
    Woodle ES; Xu D; Zivin RA; Auger J; Charette J; O'Laughlin R; Peace D; Jollife LK; Haverty T; Bluestone JA; Thistlethwaite JR
    Transplantation; 1999 Sep; 68(5):608-16. PubMed ID: 10507477
    [TBL] [Abstract][Full Text] [Related]  

  • 39. OKT3 salvage therapy in a quadruple immunosuppressive protocol in cadaveric renal transplantation.
    D'Alessandro AM; Pirsch JD; Stratta RJ; Sollinger HW; Kalayoglu M; Maki DG; Belzer FO
    Transplantation; 1989 Feb; 47(2):297-300. PubMed ID: 2493176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention and treatment of severe hemodynamic compromise in pediatric heart transplant patients.
    Costello JM; Pahl E
    Paediatr Drugs; 2002; 4(11):705-15. PubMed ID: 12390042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.